Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.43 |
| ▸ | NOS3 | P29474 | 6/20 | 0.41 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | S100B | P04271 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3425848 | 0.98 | NOS1 (0.42) | NOS1NOS3NOS2TAAR1RAD52 | |
| SCHEMBL3872243 | 0.80 | NOS1 (0.46) | NOS1NOS3NOS2TAAR1RAD52 | |
| SCHEMBL15556560 | 0.78 | SKP2 (0.50) | NOS2S100B | |
| SCHEMBL7971745 | 0.76 | NOS1 (0.40) | NOS1NOS3NOS2RAD52SLC6A4 | |
| SCHEMBL29229089 | 0.74 | TAAR1 (0.37) | NOS1NOS3NOS2TAAR1 | |
| SCHEMBL787641 | 0.73 | NOS1 (0.37) | NOS1NOS3NOS2TAAR1RAD52 | |
| SCHEMBL21358258 | 0.72 | HTR6 (0.40) | NOS1NOS3NOS2TAAR1 | |
| SCHEMBL23861145 | 0.70 | NOS1 (0.46) | NOS1 | |
| SCHEMBL15556702 | 0.70 | KDM4E (0.35) | S100B | |
| SCHEMBL23579152 | 0.69 | SKP2 (0.46) | NOS1NOS3NOS2SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2231625-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| EP-1971606-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | NOS1 2965/4885NOS3 2568/4885NOS2 3090/4885 |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | NOS1 4573/4885NOS3 4156/4885NOS2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.